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ABSTRACT
Recent years have seen an explosion in the numbers of extented spectrum class A b-lactamases (ESBLs).
The steady-state kinetic parameters for hydrolysis of b-lactams by ESBLs is discussed in the light of what
is known about the structure of these mutant enzymes.
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INTRODUCTION
Recent years have seen the rapid increase in
plasmid-encoded class A b-lactamases in clinical
populations of pathogenic Gram-negative bacte-
ria (Fig. 1). Of particular importance are variants
of the broad-spectrum b-lactamases derived from
TEM-1, TEM-2 and SHV-1 that have acquired
mutations that extend their substrate speciﬁcity to
include the advanced-generation cephalosporins
such as cefotaxime, ceftriaxone and ceftazidime.
The focus of this review will be to examine what
is known about the way in which the mutations
enable the hydrolysis of these important antimi-
crobial agents.
KINETIC MECHANISMS
Before examining the mutations that have been
identiﬁed in extended-spectrum b-lactamases (ES-
BLs), it is worthwhile considering what effects
mutation might be expected to have on the
observable steady-state kinetic parameters. It is
reasonable to suppose that the consequence of a
spectrum-expanding point mutation will be to
change one or more of the microscopic rate
constants that describe the catalytic mechanism.
Such alterations will be manifest in the steady-
state kinetic parameters that, as shown in Fig. 2,
are composite terms involving different combina-
tions of the microscopic rate constants.
The turnover number, kcat, depends on the rates
of interconversion of the intermediates, especially
the rates of formation and hydrolysis of the acyl–
enzyme complex. Therefore, it is the best para-
meter to describe the hydrolytic activity of b-lac-
tamases. This steady-state kinetic parameter will
serve to identify any mutations that affect the
reactivity of the free enzyme towards b-lactams,
as well as mutations that affect the hydrolysis
step. It does not, however, serve to identify
mutations that affect the recognition of substrates
by the enzyme.
The apparent afﬁnity or half-saturation con-
stant, KM, is frequently referred to as the Micha-
elis constant because of its equivalence to the
half-saturation constant deﬁned for the Michael-
is–Menten mechanism (which does not, however,
include a covalent intermediate). The KM includes
all the rate constants describing the catalytic steps
of b-lactam hydrolysis. Hence, it is the steady-
state kinetic parameter that should be most
sensitive to the effects of mutations, and is the
parameter best suited to the identiﬁcation of
extended-spectrum mutants.
The apparent second-order rate constant,
kcat ⁄KM, has also been used as a basis to character-
ise ESBLs and is frequently called ‘catalytic
efﬁciency’. However, as can be seen in Fig. 2, this
constant depends only on the rate constants
involved in the formation of the acyl–enzyme
intermediate, and none of the steps involved in
hydrolysis contribute. It is therefore inappropriate
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to call this parameter ‘catalytic efﬁciency’. kcat ⁄KM
is independent of the hydrolytic activity of the
enzyme, and no mutations that affect the rate of
hydrolysis of the ester or release of hydrolysed
product will change this parameter. Mutations
that affect the recognition of substrate by the
enzyme, or the reactivity of the enzyme towards
b-lactams, will affect kcat ⁄KM.
The effects of mutations that increase the ability
to hydrolyse a particular substrate are, mostly,
likely to be manifest as: (1) the association rate (k1)
increases; (2) the dissociation rate (k1) decreases;
(3) the acylation rate (k2) increases; and (4) the
hydrolysis rate (k3) increases. The effects of such
changes in the microscopic rate constants on the
steady-state kinetic parameters are summarised
in Table 1. Signiﬁcant change in kcat (>ten-fold)
can only occur if k2 and k3 are both altered;
signiﬁcant changes in KM could result from
changes in the association and dissociation rates
or the hydrolysis rate, while large changes in
kcat ⁄KM should only be expected as a result of an
increased rate of association.
BRANCHED PATHWAYS AND
CONFORMATIONAL CHANGE
Experience has shown that the simple mechanism
discussed above is frequently inadequate to
describe the kinetic mechanism of b-lactamases.
The most frequently invoked causes of departure
from the simple mechanism are branched path-
ways, in which partitioning between parallel
reaction pathways may occur [1]. The branch
may be the result of a chemical rearrangement of
the substrate triggered by the attack of the
enzyme on the b-lactam moiety, or it might result
from a change in the conformation of the protein
triggered by binding of, or reaction with, the
b-lactam. It is quite probable that both events may
occur in some reactions. Two simple cases (Fig. 3)
are considered below.
Table 1. Changes in steady-state kinetic parameters as a consequence of individual changes in rate constants
Change in
microscopic rate
constant
Effect on steady-state kinetic parameter
kcat KM kcat ⁄KM
K1 increases No effect Decreases proportionately Increases proportionately
K–1 decreases No effect Decreases proportionately Reaches limiting value when k2 > k)1
K2 increases Reaches limiting value
when k2 > k3
Reaches limiting value
when k2 > k3
Reaches limiting value when k2 > k)1
K3 increases Reaches limiting value
when k3 > k2
Decreases proportionately No effect
K2 and k3 increase Increases proportionately Reaches limiting value
when k2 > k)1
Reaches limiting value when k2 > k)1
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Fig. 1. Increasing incidence of extended-spectrum class A
b-lactamases. The cumulative total number of extended-
spectrum variants of TEM (dashed line), SHV (dotted line)
and CTX-M (solid line) series is shown as a function of the
year in which the isolates were ﬁrst reported. Data
compiled from http://www.lahey.org/studies/webt.htm
Fig. 2. A simple mechanism for hydrolysis.
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Chemical rearrangement of the acyl moiety
Chemical rearrangement of the acyl moiety
derived from the substrate has been described
for several cephalosporins and for compounds
known as b-lactamase inhibitors (often poor
substrates) [1].
Formally, the rearrangement can be considered
to occur at the ﬁrst acyl–enzyme intermediate and
to generate a second acyl–enzyme species that is
more slowly hydrolysed than the ﬁrst (Scheme 1,
Fig. 3). In this mechanism, the turnover number,
kcat, reﬂects the acylation rate, the rates of hydro-
lysis of the individual acyl–enzymes and the rate
of their interconversion (k5). If the isomerisation
reaction is signiﬁcantly faster than the rate of
hydrolysis of the un-isomerised acyl–enzyme,
then kcat will depend only on the acylation
rate and the hydrolysis rate of the isomerised
complex.
Chemically, the rearrangements typically in-
clude loss of a proton from the nitrogen atom that
was formerly part of the b-lactam ring through
ring-opening and double-bond formation (Fig. 4).
This species may go on to form further interme-
diates (see below), but loss of the proton appears
to be sufﬁcient to render this species relatively
inert for class A b-lactamases [1].
Mutations can affect the course of branched
pathways in several ways. For example, those
mutations that change charged residues (e.g., the
Glu104Lys mutation in TEM-3) will alter the
dielectric constant and hydrogen-bonding pat-
terns in the active site region where the chemical
rearrangement is taking place. This could very
strongly affect the rates of proton transfer and
charge separation in any of the rearrangements.
This, in turn, could allow new branch points, or
could account for a branch point being passed by
if the reaction constituting the branch becomes
relatively slow.
Conformational change in the enzyme
Conformational change in the protein during its
reaction with substrates has been postulated for
a number of b-lactamases. Indirect experimental
evidence of signiﬁcant changes in protein con-
formation has been obtained from reactions in
solution, particularly from spectroscopic and
stability measurements [1,2]. For example, exten-
sive hydrogen-to-deuterium exchange with the
deuterated solvent during the deacylation reac-
tion of TEM-3 was detected by time-resolved
Fourier-transform infrared spectroscopic studies
[3], suggesting that there must be a substantial
structural change during the deacylation process
that allows access to the core of the protein. As
yet, there is little evidence of such changes
from X-ray crystallographic studies of reactions
occurring with the crystallised protein, or
from proteins crystallised after reaction with
inhibitors [4–6]. This dichotomy leads to an
inadequacy in describing the mechanism of
b-lactamases and necessitates further investi-
gation of these reactions using techniques such
as nuclear magnetic resonance [7] and infrared
spectroscopy [3], which can generate time-
resolved structural information from solution
reactions.
The consequences of protein conformational
change will be manifest in the steady-state kinetic
parameters according to the step at which the
change occurs (Fig. 3). The most probable steps
with which conformation change might be asso-
ciated are the formation of the ﬁrst acyl–enzyme
intermediate and the breakdown of the enzyme–
product complex. Isomerisation of the free
enzyme, e.g., between less active and more active
states, has also been described [8]. If only the
bound species exist in two (or more) conforma-
tions, and the enzyme relaxes to ground-state
upon release of product, the steady-state kinetic
parameters will show the same dependency on
the microscopic rate constants as discussed above
for the case where the acyl moiety undergoes
chemical rearrangement. On the other hand, if the
E + L E.L E-I E.P
E-I* E.P*
E + P
(1)  Acyl moiety isomerizes
(2) Enzyme isomerizes
E + L E.L E-I E.P  E + P
E*-I E*.P E* + P
+
LE*.L 
Fig. 3. Branched pathways.
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free species of the enzyme also undergoes isom-
erisation, the possibility of parallel catalytic cycles
exists, and the reaction may proceed through
multiple phases as it settles down to a steady state
in which the partition between the parallel cycles
is determined by the relative magnitude of
the respective rate constants for catalysis and
the isomerisation rates [8].
Mutations that affect the ﬂexibility of the
protein may have consequences for the reaction
Fig. 4. Examples of rearrangement
of the acyl moiety during reaction of
b-lactams with b-lactamases. (a)
Cephalosporins (e.g., cephalothin).
(b) Carbapenems (e.g., imipenem).
(c) Oxapenems (e.g., clavulanic
acid). (d) Penam sulfones (e.g., sul-
bactam).
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pathway if they are involved in the substrate-
induced conformational change.
SUBSTRATES AND INHIBITORS
Benzylpenicillin
N
S
N
H
O
O
O
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Benzylpenicillin is rapidly hydrolysed by most
class A b-lactamases and exhibits simple, linear
kinetics where analysis has been undertaken.
Although chemical rearrangement consequent
upon opening of the thiazolidine ring would
be possible [9], this does not appear to be of
any signiﬁcance in the enzymes under consid-
eration.
Cephalothin and cephaloridine
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Cephalothin and cephaloridin, both of which are
ﬁrst-generation cephalosporins, react rapidly with
class A b-lactamases and are readily hydrolysed
by most. Both have potential leaving groups in the
3¢-substituents, making possible the elimination
and chemical rearrangement (Fig. 3a) that occurs
during the reaction with the enzyme [10,11].
Branched pathways with transient inhibition or
non-linear kinetics may therefore be observed
with some enzymes. The acetoxy substituent of
cephalothin is a better leaving group than the
pyridinium of cephaloridine, and the elimination
may be nearly concomitant with acylation for the
former compound, whereas the b-lactam hydro-
lysis product still bearing the 3¢-leaving group
may be released into solution during the reaction
of cephaloridine with some enzymes [10]. Thus,
interpretation of changes in kinetic parameters
for the hydrolysis of these cephalosporins, and
cephaloridine in particular, has to be cautious.
Cefotaxime
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Cefotaxime was one of the earliest third-genera-
tion cephalosporins, which are characterised by
the oxyimino acyl side chain. Compared to the
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Fig. 5. Frequent loci for substitutions affecting the sub-
strate speciﬁcity of class A b-lactamases.
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side chains of benzylpenicillin and the ﬁrst-
generation cephalosporins, the oxyimino side
chain is large and inﬂexible, making it more
difﬁcult to accommodate in the active site of
class A b-lactamases. As discussed below, many
of the substitutions found in ESBLs are thought to
help ameliorate this poor ﬁt. Cefotaxime has the
same 3¢-substituent as cephalothin and is there-
fore conveniently compared with the latter when
examining the effects of mutations on kinetics.
Ceftazidime
N
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Ceftazidime is also a third-generation cephalo-
sporin. It has the same 3¢-substituent as cephalor-
idine and is best compared with this compound
when examining the effects of mutations. The
oxyimino group has an additional negative
charge that would normally be repelled by acidic
side chains in the periphery of the class A active
site (Glu104, Glu240), and several of the mutants
with enhanced activity towards ceftazidime have
lysine substituted for glutamate at one or both of
these positions.
Aztreonam
N
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N
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N O
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Aztreonam is a monobactam with the same
acylamino side chain as ceftazidime. It has little
propensity towards chemical rearrangement and
is therefore convenient for checking whether
mutations affect only the side chain interactions
or have a wider inﬂuence on the branching
pathways open to ceftazidime.
MUTATIONS LEADING TO CHANGES
IN SUBSTRATE SPECIFICITY OF
CLASS A b -LACTAMASES
Hot spots in class A variants
Substitutions at 87 loci have been identiﬁed in
class A b-lactamases belonging to the TEM, SHV
and CTX-M series. There is a considerable spread
in the incidence of such substitutions (Fig. 5) and,
of course, not all affect the kinetic properties of
the enzymes. The most frequently occurring
mutations cluster in several groups: in the a1–b1
strands, in the W-loop, in the b3–b4 strands and in
the b5 strand. In addition, there are highly
prevalent point mutations at positions 69, 104
and 182 in enzymes of the TEM series.
Table 2. Kinetic parameters for hydrolysis of substrates by TEM-109 (Met69Leu, Glu104Lys, Arg164His) and TEM-6
(Glu104Lys, Arg164His)
Compound
Kinetic parameters
kcat ( ⁄ s) KM (lM) kcat ⁄KM ( ⁄mM ⁄S)
TEM-6 TEM-109 (CF) TEM-6 TEM-109 (CF) TEM-6 TEM-109 (CF)
1 134 171 (0.28) 10 20 (1) 13 8 ()0.6)
2 74 15 ()3.9) 247 181 ()0.4) 0.3 0.1 ()2)
4 9 21 (1.3) 71 330 (3.6) 0.1 0.1 (0)
5 105 56 ()0.9) 247 226 ()0.1) 0.4 0.2 ()1)
6 22 38 (0.7) 51 130 ()1.5) 0.3 0.4 (0.3)
Data taken from Robin et al. [21]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄parameter of
‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 – (parameter
of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
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Substitutions in the a1–b1 region
Substitutions in the a1–b1 region include those at
position 21 (TEM-4 and derivatives, TEM-67),
position 35 (SHV2A and derivatives, TEM-130),
position 39 (TEM-2 and derivatives) and posi-
tion 43 (SHV-7 and derivatives). As yet, no
substitution in this region has been shown to
have a signiﬁcant effect on the steady-state kinetic
mechanism. The substitutions may effect secre-
tion of the pre-protein, folding kinetics, or stabil-
ity of the folded protein (e.g., the Tm of TEM-2 is
54.7C compared to 51.5 C for TEM-1) [12].
Substitutions at position 69
Substitutions at position 69 are associated with an
inhibitor-resistant phenotype when present as a
single substitution (e.g., in TEM-33 or SHV-49)
but are also found in combination with substitu-
tions associated with an extended-spectrum phe-
notype (e.g., TEM-35). The substitutions replace
methionine with an aliphatic amino-acid (valine,
isoleucine or leucine) and generally result in
decreased kcat and a lower kcat ⁄KM (Table 2). The
decrease in reactivity of the enzyme is beneﬁcial
in slowing down the reaction with inhibitors such
as clavulanic acid, altering the balance between
acylation and rearrangement along the complex
reaction pathways that ensue after acylation.
X-ray crystallography suggests that the substi-
tutions of methionine affect the position of Ser70
or distort the active site, causing misalignment of
Ser70 and Ser130 [5]. These alterations in local
structure of critical catalytic residues are consis-
tent with the decreased turnover and lower
apparent afﬁnity of the mutant enzyme.
Substitution at position 104
The glutamate-to-lysine change at position 104 is
one of the commonest substitutions in the TEM
series, being found in 41 variants. It is rare as a
single mutation but is frequently combined with
substitutions at positions 164 (19 variants), 239 (19
variants) and 182 (12 variants). It has also been
found in combination with substitutions at posi-
tions 237 (ﬁve variants), 265 (ﬁve variants) and
240 (three variants). The substitution has not yet
been found in natural isolates of SHV but site-
directed mutants have been studied [13].
Themutation has a slightly negative effect on the
kinetic parameters for hydrolysis of the rapidly
hydrolysed substrates 1–3 but results in increased
values of kcat for b-lactams with oxyimino side
chains 4–6 (Table 3). The mutation also produces a
signiﬁcant change inKM for ceftazidime, which has
been attributed to interaction between the nega-
tively charged side chain of the b-lactam and the
new positive charge at position 104. However,
there must be other factors involved, as the KM of
themutant for aztreonam, which has the same side
chain as ceftazidime, does not change very much.
The pattern of changes in kinetic parameters
strongly suggests a selective increase in the asso-
ciation rate (k1 in Fig. 1) and in the rates of acylation
and deacylation (k2 and k3) for substrates 4–6. This
would be consistent with widening of the active
site to admit the larger oxyimino side chain (affects
k1) and to speciﬁcally improve its orientation with
Table 3. Kinetic parameters for hydrolysis of substrates by TEM-1 and a mutant with lysine at position 104
Compound
Kinetic parameters
kcat ( ⁄ s) KM (lM) kcat ⁄KM ( ⁄mM ⁄ s)
E104 K104 (CF) E104 K104 (CF) E104 K104 (CF)
1 1100 840 ()0.32) 24 21 ()0.14) 45 000 40 000 ()0.12)
2 150 150 (0) 260 240 ()0.08) 600 620 (0)
3 1000 670 ()0.5) 370 600 (0.62) 2700 1100 ()1.4)
4 2 25 (12.5) 1100 1000 ()0.1) 1.8 25 (13)
5 0.02 0.3 (14) 300 80 ()2.8) 0.066 3.7 (56)
6 0.2 2.5 (11.5) 200 160 ()0.25) 1 16 (15)
Data taken from Petit et al. [22]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄parameter of
‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 – (parameter
of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
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respect to the catalytic centre, so that attack on the
b-lactam ring (k2) is more efﬁcient. The improved
orientation would also appear to be preserved in
the acyl–enzyme complex, such that its hydrolysis
(k3) is also enhanced.
Substitutions in the W-loop
Substitutions in the W-loop are the commonest in
the TEM series, with at least 42 derivatives known
with replacements at Arg164. The residue is
mutated to serine (23 variants), histidine (16 vari-
ants) and rarely cysteine (three variants). It may be
the only mutation present in a variant that affects
the kinetic mechanism (TEM-7, -12, -29, -53, -115
and -143) or, more commonly, it is found in
combination with other substitutions that are
known to also modify the kinetics. These include
substitutions at positions 104 (19 variants), 237
(eight variants), 238 (three variants), 240 (14 vari-
ants) and 265 (seven variants). The combination of
substitutions at positions 164 and 238 does appear
to be very favourable, as only three of the 33
variants with the substitution at position 238 also
have a substitution at position 104.
The substitutions signiﬁcantly impair the
hydrolysis of substrates 1–3, with large decreases
in kcat and KM resulting in ﬁve-to ten-fold
decreases in kcat ⁄KM (Table 4). In contrast, kcat ⁄KM
for the hydrolysis of oxyimino cephalosporins is
increased more than ﬁve-fold. For cefotaxime (4),
this is the result of an increase in apparent afﬁnity
(KM is signiﬁcantly lower), whereas the apparent
afﬁnity decreases but the turnover number is
greatly increased for ceftazidime and, to a lesser
extent, aztreonam, (Table 4). The pattern of
changes strongly suggests that the association
rate is increased for all substrates but, while the
mutation improves the alignment of the oxyimino
substrates, this is at the expense of alignment of
the substrates with small side chains (1–3), for
which the hydrolysis rate drops markedly.
X-ray crystallography of mutants with this sub-
stitution suggests that the pattern of hydrogen
bonding in the binding pocket that receives the
acylamino side chain is altered in themutants. This
could explain why the consequences of this muta-
tion appear to be manifest in different ways, acc-
ording to the acylamino side chain of the substrate.
Substitution at position 182
Substitution at position 182, in which methionine
is replaced with threonine (19 times) or isoleucine
(once), is only found in the TEM series. It is
relativelymore common amongTEM-1derivatives
(16%) than among TEM-2 derivatives (6%). It has
only minor consequences for the kinetics of the
enzymes in which it is found (changes in any of the
parameters are usually less than ﬁve-fold [6,14]),
and the mutant occurs as a natural variant (TEM-
135) that has properties similar to TEM-1 [15]. The
substitution affects the dynamics of folding of
nascent protein [14,16] or the thermal stability of
the folded protein [6], and has therefore been
suggested to ameliorate the deleterious effects of
other mutations on expression of b-lactamase
activity [6,14,16,17]. It is frequently found in
combination with substitutions that have little
deleterious effect on thermal stability of the folded
Table 4. Kinetic parameters for hydrolysis of substrates by TEM-7 (Arg164) and TEM-1
Compound
Kinetic parameters
kcat ( ⁄ s) KM (lM) kcat ⁄KM ( ⁄mM ⁄ s)
TEM-1 TEM-7 (CF) TEM-1 TEM-7 (CF) TEM-1 TEM-7 (CF)
1 1600 40 ()39) 19 3.1 ()5) 84 000 13 000 ()5.5)
2 160 20 ()7) 246 80 ()2) 650 250 ()1.6)
3 1500 26 ()58) 682 87 ()6.8) 2200 300 ()6.3)
4 9 1.5 ()5) 6000 100 ()59) 1.5 15 (9)
5 0.3 9 (30) 4300 1000 ()3.3) 0.07 9 (2300)
6 1 4 (3) 1430 1333 (0.1) 0.7 3 (3.2)
Data taken from Raquet et al. [23]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄parameter of
‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 – (parameter
of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
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protein (e.g., Glu104Lys) and it is uncommon
among the thermally more stable TEM-2 deriva-
tives. If it is not simply a natural polymorphism,
then the selection may be for increased stability,
regardless of the effects of other mutations.
Substitutions in the b3-strand
Mutations at three positions in the b3-strand,
which forms one edge of the catalytic centre, have
been observed.
Table 6. Kinetic parameters for hydrolysis of substrates by SHV-2A (Gly238Ser) and SHV-1
Compound
Kinetic parameters
kcat ( ⁄ s) KM (lM) kcat ⁄KM ( ⁄ lM ⁄ s)
SHV-1 SHV-2A (CF) SHV-1 SHV-2A (CF) SHV-1 SHV-2A (CF)
1 250 150 ()0.67) 40 13.5 ()1.9) 6.3 11 (0.7)
2 19 29 (0.52) 42 8 ()4.3) 0.5 3.6 (6.2)
3 290 108 ()1.7) 220 25 ()8.1) 1.3 4.3 (2.3)
4 NMa 15 (NM) >300 11.4 (<)25) – 1.3 (>25)
aNM, not measurable.
Data taken from Lee et al. [25]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄parameter of
‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 – (parameter
of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
Table 5. Kinetic parameters for hydrolysis of substrates by TEM-24 (39Lys, Glu104Lys, Arg164Ser, Ala237Thr, Glu240Lys)
and TEM-46 (39Lys, Glu104Lys, Arg164Ser, Glu240Lys)
Compound
Kinetic parameters
Vmax relative to hydrolysis
of 1 KM (lM)
Vmax ⁄KM
relative to hydrolysis of 1
TEM-46 TEM-24 (CF) TEM-46 TEM-24 (CF) TEM-46 TEM-24 (CF)
2 0.46 2.8 (5.1) 100 43 ()1.3) 0.02 0.36 (17)
4 0.13 1.3 (9.0) 50 50 (0) 0.01 0.14 (13)
5 0.19 14 (73) 159 380 (1.4) 0.06 0.21 (2.5)
6 0.35 1.2 (2.4) 12 42 (2.5) 0.09 0.17 (0.89)
Data taken from Chanal-Claris et al. [24]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄param-
eter of ‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 –
(parameter of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
Table 7. Kinetic parameters for hydrolysis of substrates by TEM-10 (Arg164Ser, Glu240Lys) and TEM-12 (Arg164Ser)
Compound
Kinetic parameters
Vmax relative to hydrolysis
of 3 KM (lM)
Vmax ⁄KM
relative to hydrolysis of 3
TEM-12 TEM-10 (CF) TEM-12 TEM-10 (CF) TEM-12 TEM-10 (CF)
1 1.8 1.7 ()0.1) 20 5.8 ()2.4) 90 293 (2.2)
4 0.04 0.09 (1.3) 94 46 ()1) 0.43 2.0 (3.7)
5 0.07 2.0 (28) 130 150 (0.15) 0.54 13 (23)
6 0.11 0.32 (1.9) 870 28 ()30) 0.13 11 (84)
Data taken from Queenan et al. [26]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄parameter of
‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 – (parameter
of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
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Substitution of Ala237 for threonine or glycine
is relatively uncommon (eight variants and only
once, for threonine and glycine, respectively). The
mutations increase both kcat and KM, but with a
greater effect on the former parameter, resulting
in an increase of kcat ⁄KM for most substrates
(Table 5).
Substitution of Gly238 for serine is very
commonly encountered in the TEM and SHV
series (32 variants and 22 variants, respectively).
Substitution with aspartate (TEM-111) and ala-
nine (SHV-13, -18 and -29) has also been
observed. The mutations result in decreased
turnover (kcat) of simple substrates such as
benzylpenicillin and cephaloridine, although the
apparent afﬁnity (KM) increases, and therefore
kcat ⁄KM for these substrates is two- to three-fold
greater in the mutants (Table 6). The effect on
the hydrolysis of substrates with oxyimino acyl
side chains is more marked, with signiﬁcant
increases in kcat and kcat ⁄KM. X-ray crystallogra-
phy of enzymes with 238 substitutions shows a
signiﬁcant displacement in the 238–242 b-strand-
turn segment, making the b-lactam-binding site
more open [18]. In SHV-2, the b-strand is
displaced by 1.6 A˚ with respect to its position
in SHV-1 [18], while in TEM-52 [19] the loop
between the b3 and b4 strands is moved by as
much as 2.8 A˚ with respect to its position in
TEM-1 and, in particular, the side chain of
Glu240 is removed from the active site. The
consequent widening of the active site could
help to accommodate the larger oxyimino side
chain, and the movement of Glu240 decreases
the possibility of its interference with the sub-
strate side chain.
Substitution of Glu240 for lysine is commonly
encountered in the TEM and SHV series (22
variants and 15 variants, respectively). Substitu-
tion with arginine has also been observed
(SHV-86). The substitution increases the apparent
afﬁnity (KM) for most substrates, with little effect
on turnover (kcat), except for ceftazidime and
aztreonam, for which the kcat is increased more
than three-fold (Table 7). These effects are not
entirely consistent with the suggestion from
crystallography that the side chain at position 240
causes steric hindrance to the binding of the
substrate side chain, as the Glu240Lys substitu-
tion introduces a larger side chain. However, in
the TEM series, the Glu240Lys substitution is
always combined with substitutions at either
Arg164 or Gly238, both of which affect the
ﬂexibility of the protein in the vicinity of Glu240
and could, therefore, ameliorate the effect of
introducing a larger residue in this position.
There are even three TEM variants with lysines
at positions 104 and 240 that project from either
side of the side chain-binding pocket of the active
site (TEM-24, -46 and -121) and would potentially
close the end of the active site, but these all have
the W-loop mutation.
Substitutions at position 244
Substitutions at position 244 are associated with
an inhibitor-resistant phenotype when present as
a single substitution (e.g., in TEM-30, -31, -44, -51,
Table 8. Kinetic parameters for hydrolysis of substrates by TEM-121 (Glu104Lys, Arg164Ser, Ala237Thr, Glu240Lys,
Arg244Ser) and TEM-24 (Glu104Lys, Arg164Ser, Ala237Thr, Glu240Lys)
Compound
Kinetic parameters
kcat ( ⁄ s) KM (lM) kcat ⁄KM ( ⁄mM ⁄ s)
TEM-24 TEM-121 (CF) TEM-24 TEM-121 (CF) TEM-24 TEM-121 (CF)
1 20 25 (0.25) 9 15 (0.67) 2200 1700 ()0.29)
2 30 20 ()0.5) 30 420 (13) 1000 50 ()19)
3 90 70 ()0.28) 90 270 (2) 1000 260 ()2.7)
4 8.5 0.5 ()16) 25 430 (8.2) 340 10 ()33)
5 120 40 ()2) 180 150 ()0.2) 670 270 ()1.5)
6 16 6.5 ()1.5) 55 80 (0.6) 290 80 ()2.6)
Data taken from Poirel et al. [27]. CF indicates the change factor, calculated as CF = (parameter of mutant ⁄parameter of
‘parent’) – 1, when the value of the parameter of the mutant is greater than that of the ‘parent’, and as CF = 1 – (parameter
of ‘parent’ ⁄parameter of mutant), when the value of the parameter of the mutant is less than that of the ‘parent’.
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-54, -65) but are also found in combination with
substitutions associated with an extended-spec-
trum phenotype (e.g., TEM-121). The substitu-
tions replace arginine with a smaller amino-acid
(serine, cysteine, histidine, leucine or glycine).
The mutations decrease kcat for most substrates
and increase KM for many, resulting in lower
kcat ⁄KM for all (Table 8). The decrease in reactivity
of the enzyme is beneﬁcial in slowing down the
reaction with inhibitors such as clavulanic acid,
altering the balance between acylation and rear-
rangement along the complex reaction pathways
that ensue after acylation.
X-ray crystallography suggests that the sub-
stitution of arginine with a shorter amino-acid
disrupts the hydrogen bond pattern that runs
from this residue to Ser130 in the active site. The
alterations in local structure and hydrogen-
bonding may explain the decreased turnover
and the lower apparent afﬁnity of the mutant
enzyme. Mutations at position 276 displace the
side chain of Arg244 through altered interaction
with its guanidine head group and have similar
negative effects on the kinetics of the mutant
enzyme, as does the direct replacement of
Arg244 [20].
CONCLUSION
Class A b-lactamases appear to be well-ordered
molecules in the ground-state but there is abun-
dant evidence that they undergo several confor-
mational changes induced by binding and
reaction with substrates and mechanism-based
inhibitors. These conformational changes result in
branching reaction pathways that give a complex
kinetic mechanism. It is probable that some of the
mutations observed in clinical isolates affect the
rate at which or extent to which these conforma-
tional changes occur and thus alter the partition
between different branches of the pathways. This
is an aspect that has yet to be studied in detail
with any of the hundreds of variants that have
been identiﬁed.
Furthermore, many substrates, and nearly all of
the mechanism-based inhibitors, have the poten-
tial to undergo chemical rearrangement triggered
by the attack of the enzyme on the b-lactam ring
that can also lead to branched pathways and
complex kinetics, which can be overlaid on the
protein conformational change. Only the reactions
with a few mechanism-based inhibitors have been
studied, and a detailed description of the kinetic
mechanism of any in terms of the structures of the
intermediates and their rates of interconversion is
lacking.
X-ray crystallography provides static pictures
of several points in the reaction pathway and the
preliminary basis for understanding the nature of
the changes in protein structure consequent on
the mutations. The relevance of any of the
structures to the reactions occurring in solution
is still uncertain, as none of the crystal structures
provides an explanation for the protein confor-
mational changes indicated by solution studies.
Application of spectroscopic techniques such as
nuclear magnetic resonance and Fourier-trans-
form ⁄ infrared, which can provide time-resolved
structural information, will be important in bridg-
ing this gap in our understanding.
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